AI

AirSculpt Technologies, Inc.

AIRSHealthcareNASDAQ

Medical Care Facilities · Last scanned Sep 9, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$151.8M
-15.8% YoY
Net Income
-$11.7M
-45.5% YoY
EBITDA
$1.2M
-88.2% YoY
Free Cash Flow
$8.0M

Scan Results

Daily timeframe
5 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3 RSI OversoldRSI 21.6, below 30, stock may be oversold
Sep 2 RSI OversoldRSI 25.9, below 30, stock may be oversold
About AirSculpt Technologies, Inc.

AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United. The $195.0M market capitalization puts AIRS squarely in micro-cap range for its industry. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure.

Where AIRS stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, AIRS finished 29.31% below its 150-day moving average ($3.48) and 25.90% below its 200-day moving average ($3.32). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is AIRS overbought or oversold?

At the September 3, 2026 close, AIRS's RSI(14) was 21.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$195.0M
Fwd P/E-270.50
EPS$-0.18
Beta2.29
52W Change-54.2%
ROE-12.0%
Analysis

The company holds $18.8M in cash, though total debt stands at $70.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $8.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -12.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $168.8M (2022) to $151.8M (2025), a 10% decline worth watching.

A beta of 2.29 means AIRS is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AIRS.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms